Mapp Biopharmaceutical is an American pharmaceutical company founded in 2003 by Larry Zeitlin and Kevin Whaley.

under development and comprises three humanized monoclonal antibodies used as a treatment for Ebola virus disease.

[3][4] The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak.

[3] The antibody work came out of research projects funded by Defense Advanced Research Projects Agency (DARPA) more than a decade ago,[1] and years of funding by the Public Health Agency of Canada.

[6] ZMapp is manufactured in the tobacco plant Nicotiana benthamiana in the bioproduction process known as "pharming" by Kentucky BioProcessing, a subsidiary of Reynolds American.